| Business Summary | | Cell
Pathways
Holdings
(CPI)
is
a
development-stage
pharmaceutical
company
focused
on
the
research,
development
and
commercialization
of
products
to
prevent
and
treat
cancer.
The
Company's
technology
is
based
upon
the
discovery
of
a
novel
mechanism
that,
based
on
the
Company's
research,
can
be
targeted
to
induce
selective
apoptosis
in
pre-cancerous
and
cancerous
cells
(neoplastic
cells)
without
affecting
apoptosis
in
normal
cells.
Apoptosis
is
a
naturally
occurring
physiological
process
wherein
a
number
of
components
inside
a
cell
program
the
cell
to
die
without
causing
harm
to
surrounding
cells.
The
Company
has
created
a
new
class
of
selective
apoptotic
anti-neoplastic
drugs
(SAANDs)
and
has
synthesized
many
new
chemical
compounds
in
this
new
class.
In
screening
assays,
many
of
these
new
compounds
have
displayed
greater
apoptotic
potency
than
the
Company's
lead
drug
candidate,
Aptosyn
(exisulind). | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cell
Pathways
Holdings
is
a
pharmaceutical
company
focused
on
the
research,
development
and
commercialization
of
products
to
prevent
and
treat
cancer.
For
the
six
months
ended
6/30/01,
revenues
totaled
$317
thousand
vs.
no
revenue.
Net
loss
fell
30%
to
$9.6
million.
Revenues
reflect
the
agreement
with
Aventis
Pharmaceuticals
for
marketing
Nilandron.
Lower
loss
also
reflects
the
reductions
in
the
purchase
of
raw
materials
for
Aptosym
and
decreased
marketing
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Robert Towarnicki, 49 Chairman,
Pres, CEO | $280K | -- | Brian Hayden, 49 CFO,
VP-Fin., Treasurer | 190K | $2.1M | Rifat Pamukcu, M.D., 43 Exec.
VP, Director, and CSO | 212K | -- | Martha Manning, 46 Sr.
VP, Gen. Counsel, Sec. | -- | -- | Robert Bellet, M.D., 58 Sr.
VP, Clinical and Regulatory Affairs | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|